Diabetic Dyslipidemia

Rated 4.2/5 based on 1426 reviews

A Novel Therapy to treat Diabetic Dyslipidemia

Novel NCE from an Indian research pipeline to move from the lab to the market

A Novel Therapy to treat Diabetic Dyslipidemia

Zydus becomes the 1st Indian Pharma Company to launch an NCE

It’s first-of-its kind novel action works as a lipid regulator and also provides glycemic benefits

This marks the beginning of India’s contribution to the world of drug discovery

LIPAGLYN - The novel drug for treating Diabetic Dyslipidemia

combines lipid and glucose lowering effects in one single molecule.

Contact Us

Zydus medical team is here to answer any questions you may have about Lipaglyn™

Email us at lipaglyn@zydusmail.com.

Disclaimer : Lipaglyn is a prescription drug authorised for sale in India only and can be taken only under the advice and guidance of a registered medical practitioner.